Category: 877149-10-5

On July 21, 2011, Aronov, Alex; Come, Jon H.; Davies, Robert J.; Pierce, Albert C.; Wang, Jian; Nanthakumar, Suganthini; Cao, Jingrong; Bandarage, Upul K.; Krueger, Elaine; Tiran, Amaud Le; Liao, Yusheng; Messersmith, David; Collier, Philip N.; Grey, Ronald; O’Dowd, Hardwin; Henderson, James A.; Grillot, Anne-Laure published a patent.HPLC of Formula: 877149-10-5 The title of the patent was Preparation of dihydropyrrolopyridinone derivatives and analogs for use as phosphatidylinositol 3-kinase inhibitors. And the patent contained the following:

Title compounds I [A = N, CH, CCH3, or COCH3; B = N, CH, CF, etc.; or A=B is a S atom; C = N, CH, CCl, COH, etc.; D = N, CH, CCO2H, CCN, etc.; E = N, CH, CF, COH, etc.; provided no more than two A, B, C, D, or E is N; X = N or CH; Y = N, CH, or CCH3; R1 = (un)substituted Ph, heteroaryl, pyridone, fused bicyclic heteroaryl,or heterocyclic ring system; R2 = H, F, Cl, CF3, OCF3, etc.; R3 = H, (un)substituted aliphatic, cycloaliphatic, OH, etc.; R4 = H or alkyl; or R3 and R4 together with the carbon to which they are attached form an (un)substituted cycloaliphatic ring, heterocyclic ring containing up to two atoms selected from N or O, or alkenyl; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as phosphatidylinositol 3-kinase (PI3K) inhibitors. Thus, e.g., II was prepared by chlorination of Et 2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate followed by coupling with 2,3-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (preparation given), bromination, and cyclization with 2-(4-amino-1H-pyrazol-1-yl)acetonitrile. Select I were evaluated in PI3K-γ inhibition assays, e.g., II demonstrated a Ki value of less than 0.1 μM. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).HPLC of Formula: 877149-10-5

The Article related to pyridinone pyrrolo derivative preparation phosphatidylinositol kinase pi3k inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 877149-10-5

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On June 11, 2020, Lu, Hongfu; Xing, Weiqiang; Peng, Jianbiao; Guo, Haibing published a patent.Name: Methyl 4-bromo-2-chloro-6-methylbenzoate The title of the patent was Preparation of azetidinecarboxylic acid compounds as as an S1P1 agonists and immunomodulators. And the patent contained the following:

The present invention relates to azetidinecarboxylic acid compounds, the pharmaceutically acceptable salt thereof, and the uses of the compound acting as an S1P1 agonist. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).Name: Methyl 4-bromo-2-chloro-6-methylbenzoate

The Article related to azetidine carboxylate preparation s1p1 agonist immunomodulator, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.Name: Methyl 4-bromo-2-chloro-6-methylbenzoate

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On February 23, 2006, Clayton, Joshua; Ma, Fupeng; Van Wagenen, Bradford; Ukkiramapandian, Radhakrishnan; Egle, Ian; Empfield, James; Isaac, Methvin; Slassi, Abdelmalik; Steelman, Gary; Urbanek, Rebecca; Walsh, Sally published a patent.Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate The title of the patent was Preparation of isoindolones as metabotropic glutamate receptor potentiators. And the patent contained the following:

The title compounds I [R1 = (un)substituted 3-7 membered ring that may contain one or more heteroatoms selected from N, O and S; R2, R3 = H, alkyl, aryl, etc.; R4, R6 = H, OH, halo, etc.; R5 = H, halo, NO2, etc.; R7 = H, halo, NO2, etc.; R8, R9 = H, halo, NO2, etc.; or, where n is greater than 1, two or more R8 and/or R9 on adjacent carbons may be absent to form an alkenyl or alkynyl moiety], useful as metabotropic glutamate receptor modulators, particularly in neurol. and psychiatric disorders, were prepared E.g., a multi-step synthesis of II, was given. Generally, compounds I were active in assays described (e.g., mGluR2 assay) at concentrations (or with EC50 values) less than 10 μM. The pharmaceutical composition comprising the compound I is disclosed. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate

The Article related to isoindolone preparation metabotropic glutamate receptor potentiator mglur2, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On November 22, 2018, Boss, Christoph; Corminboeuf, Olivier; Fretz, Heinz; Lyothier, Isabelle; Pozzi, Davide; Richard-Bildstein, Sylvia; Siendt, Herve; Sifferlen, Thierry published a patent.Category: chlorides-buliding-blocks The title of the patent was Preparation of benzofuran and benzothiophene derivatives as PGE2 receptor modulators. And the patent contained the following:

The title compounds I [R1 = (independently) alkyl, alkoxy, halo, etc.; n = 1-3; R2 =H, alkyl, halo, or cyano; X = S or O; R3 = H, Me or CF3; R41 and R42 = (independently) H, Me; or R41 and R42, together with the carbon atom to which they are attached, represent a cycloprop-1,1-diyl group; R51 and R52 = (independently) H, Me; or R51 and R52, together with the carbon atom to which they are attached, represent a cycloprop-1,1-diyl group; Ar1 = (un)substituted Ph, or 5-6 membered heteroaryl, 8-10 membered bicyclic heteroaryl, etc.] or pharmaceutically acceptable salts thereof, useful in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor, were prepared E.g., a multi-step synthesis of {6-[4-Ethoxy-5-(1H-tetrazol-5-yl)-thiophen-2-yl]-pyrimidin-4-yl}-[2-(5-fluoro-2,7-dimethylbenzo[b]thiophen-3-yl)ethyl]amine, starting from Me 3-ethoxythiophene-2-carboxylate, was described. Exemplified compounds I were evaluated for EP2 and EP4 antagonistic activities (data given). The invention further relates to novel benzofurane and benzothiophene derivatives I and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds I, and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).Category: chlorides-buliding-blocks

The Article related to benzofuran benzothiophene pyrimidinylamino preparation prostaglandin ep2 ep4 receptor antitumor, immune response modulator cancer benzofuran benzothiophene pyrimidinylamino preparation and other aspects.Category: chlorides-buliding-blocks

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On May 14, 2020, Shepard, Stacey; Combs, Andrew P. published a patent.SDS of cas: 877149-10-5 The title of the patent was Preparation of heterocyclic derivatives as PI3K inhibitors. And the patent contained the following:

This invention relates to compounds I [Z = CZ1 or N; Z1 and R12 = (independently) H, D, OH, NO2, etc.; R1 = H, D, halo, alkyl, etc.; R2 = H, D, halo, alkyl, etc.; R6 = H, D, halo, alkyl, etc.; X9 = (un)substituted NH or CH2; X11 = (un)substituted NH or CH2; R = H, alkyl, alkenyl, etc.] or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. E.g., a multi-step synthesis of (S)-II, starting from 4-bromopyridine-2-carbonitrile, was disclosed. The exemplified compounds I were tested in the PI3Kγ, PI3Kδ, and PI3Kγ THP1 RPS6 ELISA assays (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).SDS of cas: 877149-10-5

The Article related to heterocyclic derivative preparation pi3k gamma inhibitor antitumor cardiovascular, autoimmune neurodegenerative disease treatment heterocyclic derivative preparation pi3k gamma, heteroarylpyridazinyl heteroarylpyridyl isoindolinone indazole preparation pi3k gamma inhibitor and other aspects.SDS of cas: 877149-10-5

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On May 14, 2020, Shepard, Stacey; Combs, Andrew P. published a patent.SDS of cas: 877149-10-5 The title of the patent was Preparation of heterocyclic derivatives as PI3K inhibitors. And the patent contained the following:

This invention relates to compounds I [Z = CZ1 or N; Z1 and R12 = (independently) H, D, OH, NO2, etc.; R1 = H, D, halo, alkyl, etc.; R2 = H, D, halo, alkyl, etc.; R6 = H, D, halo, alkyl, etc.; X9 = (un)substituted NH or CH2; X11 = (un)substituted NH or CH2; R = H, alkyl, alkenyl, etc.] or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. E.g., a multi-step synthesis of (S)-II, starting from 4-bromopyridine-2-carbonitrile, was disclosed. The exemplified compounds I were tested in the PI3Kγ, PI3Kδ, and PI3Kγ THP1 RPS6 ELISA assays (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).SDS of cas: 877149-10-5

The Article related to heterocyclic derivative preparation pi3k gamma inhibitor antitumor cardiovascular, autoimmune neurodegenerative disease treatment heterocyclic derivative preparation pi3k gamma, heteroarylpyridazinyl heteroarylpyridyl isoindolinone indazole preparation pi3k gamma inhibitor and other aspects.SDS of cas: 877149-10-5

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On May 14, 2020, Shepard, Stacey; Ai, Yanran; Combs, Andrew P.; Shvartsbart, Artem published a patent.Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate The title of the patent was Preparation of heterocyclic derivatives as PI3K inhibitors. And the patent contained the following:

This invention relates to compounds I [R1 = H, D, halo, alkyl, etc.; R6 = H, D, halo, alkyl, etc.; X9 = (un)substituted NH or CH2; X11 = (un)substituted NH or CH2; R = H, alkyl, alkenyl, etc.] or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. E.g., a multi-step synthesis of (S)-II.TFA, starting from Me 4-bromo-2-(bromomethyl)benzoate and (S)-1-cyclopropylethan-1-amine, was disclosed. The exemplified compounds I were tested in the PI3Kγ, PI3Kδ, and PI3Kγ THP1 RPS6 ELISA assays (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate

The Article related to heterocyclic derivative preparation pi3k gamma inhibitor antitumor cardiovascular, autoimmune neurodegenerative disease treament heterocyclic derivative preparation pi3k gamma, pyrazinyl isoindolinone indazole preparation pi3k gamma inhibitor, pyrazinamine oxoindolinyl indazolyl preparation pi3k gamma inhibitor antitumor cardiovascular and other aspects.Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On May 14, 2020, Shepard, Stacey; Ai, Yanran; Combs, Andrew P.; Shvartsbart, Artem published a patent.Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate The title of the patent was Preparation of heterocyclic derivatives as PI3K inhibitors. And the patent contained the following:

This invention relates to compounds I [R1 = H, D, halo, alkyl, etc.; R6 = H, D, halo, alkyl, etc.; X9 = (un)substituted NH or CH2; X11 = (un)substituted NH or CH2; R = H, alkyl, alkenyl, etc.] or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. E.g., a multi-step synthesis of (S)-II.TFA, starting from Me 4-bromo-2-(bromomethyl)benzoate and (S)-1-cyclopropylethan-1-amine, was disclosed. The exemplified compounds I were tested in the PI3Kγ, PI3Kδ, and PI3Kγ THP1 RPS6 ELISA assays (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of Methyl 4-bromo-2-chloro-6-methylbenzoate(cas: 877149-10-5).Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate

The Article related to heterocyclic derivative preparation pi3k gamma inhibitor antitumor cardiovascular, autoimmune neurodegenerative disease treament heterocyclic derivative preparation pi3k gamma, pyrazinyl isoindolinone indazole preparation pi3k gamma inhibitor, pyrazinamine oxoindolinyl indazolyl preparation pi3k gamma inhibitor antitumor cardiovascular and other aspects.Recommanded Product: Methyl 4-bromo-2-chloro-6-methylbenzoate

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics